Last update Oct. 17, 2024

Pioglitazone Hydrochloride

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Pioglitazone is a thiazolidinedione used in conjunction with diet and exercise to normalize blood glucose levels in adults with type 2 diabetes mellitus. It is administered orally once daily.

At the time of the last update, we found no published data on its excretion in breast milk.

Its pharmacokinetic data (very high percentage of binding to plasma proteins and large volume of distribution) make it very unlikely to pass into breast milk in clinically significant quantities.

Pending further published data on this drug in relation to lactation, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.

Some health agencies (France, Germany) have recommended the suspension of marketing of pioglitazone for being associated with an increased risk of cancer of the bladder. (IARC 2016)

Thiazolidinediones increase insulin sensitivity. Oral antidiabetics are not useful in type 1 diabetes. In type 2 diabetes, diet, exercise and breastfeeding will improve blood glucose levels.


See below the information of this related product:

  • Maternal Diabetes mellitus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

  • Acarbose (Safe product and/or breastfeeding is the best option.)
  • Glibenclamide (Safe product and/or breastfeeding is the best option.)
  • Glipizide (Safe product and/or breastfeeding is the best option.)
  • Hypocaloric Diet (Safe product and/or breastfeeding is the best option.)
  • Insulin (Safe product and/or breastfeeding is the best option.)
  • Metformin Hydrochloride (Safe product and/or breastfeeding is the best option.)
  • Miglitol (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Pioglitazone Hydrochloride in other languages or writings:

Tradenames

Main tradenames from several countries containing Pioglitazone Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 80 %
Molecular weight 393 daltons
Protein Binding > 99 %
VD 0.6 ± 0.4 l/Kg
pKa 6.7 -
Tmax 2 hours
3 - 7 (Metab: 6 - 24) hours

References

  1. IARC - WHO. International Agency for research on Cancer. Some Drugs and Herbal Products. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 108. 2016 Full text (link to original source)
  2. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract

Total visits

6,836

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM